GEN-MKT-18-7897-A
Apr 28, 2026 | Biopharma, BioPhase 8800 system, Blogs | 0 comments
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
Native fluorescence detection (NFD) strengthens CE‑SDS performance by improving both detection sensitivity and interpretability.
High sensitivity without labeling
NFD leverages intrinsic tryptophan fluorescence to detect proteins label‑free, avoiding the variability and workflow burden of dye‑labeling steps.
Technical note data show:
For scientists managing stability programs or performing forced degradation studies, this sensitivity can reveal early‑stage degradation signatures that UV cannot reliably resolve.
Clearer, more stable baselines for better integration
Typical UV electropherograms show baseline drifting due to buffer absorbance and gel heterogeneity.
The NFD baseline, however, is consistently flat, improving:
These benefits reduce manual reprocessing and strengthen data defensibility across development stages.
Multi-capillary throughput for faster studies
The BioPhase 8800 system processes 8 samples in parallel, expanding CE‑SDS throughput without requiring additional instruments or longer sequences.
High‑throughput CE‑SDS paired with NFD’s sensitivity provides a strong foundation for data‑driven therapeutic development.
A balanced upgrade path from UV and LIF
NFD complements existing detection modes:
This offers scientists flexibility while building long‑term method robustness.
Explore the CE‑SDS NFD data
For deeper review, check out the resources in our NFD solutions hub >
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network